These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 1712882)

  • 1. Alfuzosin for benign prostatic hypertrophy.
    Chapple CR
    Lancet; 1991 Jul; 338(8760):182. PubMed ID: 1712882
    [No Abstract]   [Full Text] [Related]  

  • 2. [Alfuzosin in the treatment of benign prostatic hypertrophy].
    Jardin A
    J Urol (Paris); 1993; 99(6):308-10. PubMed ID: 7516375
    [No Abstract]   [Full Text] [Related]  

  • 3. Alfuzosin for benign prostatic hypertrophy.
    Jardin A; Bensadoun H; Delauche-Cavallier MC; Attali P
    Lancet; 1991 Oct; 338(8772):947. PubMed ID: 1717801
    [No Abstract]   [Full Text] [Related]  

  • 4. [Alfuzosin in benign prostatic hyperplasia. A new principle is evaluated. Report of a study].
    Fortschr Med Suppl; 1995; 166():1-12. PubMed ID: 7537599
    [No Abstract]   [Full Text] [Related]  

  • 5. [Effectiveness of various alfuzosin schedules in patients with benign prostatic hyperplasia (BPH)].
    Loran OB; Rasner PI; Kosko D; Pushkar' DIu
    Urologiia; 2001; (1):8-10. PubMed ID: 11233234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia.
    Wilde MI; Fitton A; McTavish D
    Drugs; 1993 Mar; 45(3):410-29. PubMed ID: 7682910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended-release alfuzosin hydrochloride: a new alpha-adrenergic receptor antagonist for symptomatic benign prostatic hyperplasia.
    Guay DR
    Am J Geriatr Pharmacother; 2004 Mar; 2(1):14-23. PubMed ID: 15555475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First dose efficacy of alfuzosin once daily in men with symptomatic benign prostatic hyperplasia.
    Marks LS; Roehrborn CG; Gittelman M; Kim D; Forrest J; Jacobs S
    Urology; 2003 Nov; 62(5):888-93. PubMed ID: 14624914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A clinical trial of the treatment of patients with benign prostatic hyperplasia using the alpha 1-adrenoblocker alfuzosin].
    Lopatkin NA; Perepanova TS
    Urol Nefrol (Mosk); 1997; (5):14-6. PubMed ID: 9412005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alfuzosin (uroxatral)--another alpha1-blocker for benign prostatic hyperplasia.
    Med Lett Drugs Ther; 2004 Jan; 46(1173):1-2. PubMed ID: 14691408
    [No Abstract]   [Full Text] [Related]  

  • 11. [Alfuzosin. A new selective alpha 1 receptor antagonist for symptomatic medical treatment of benign prostatic hypertrophy prior to surgery].
    Hansen BJ; Meyhoff HH
    Ugeskr Laeger; 1992 Feb; 154(6):361-2. PubMed ID: 1371629
    [No Abstract]   [Full Text] [Related]  

  • 12. Alfuzosin in the treatment of benign prostatic hyperplasia: effects on symptom scores, urinary flow rates and residual volume. A multicentre, double-blind, placebo-controlled trial. ALFECH Study Group.
    Hansen BJ; Nordling J; Mensink HJ; Walter S; Meyhoff HH
    Scand J Urol Nephrol Suppl; 1994; 157():169-76. PubMed ID: 7524141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 12-18 month assessment. BPHALF Group.
    Jardin A; Bensadoun H; Delauche-Cavallier MC; Attali P
    Br J Urol; 1993 Nov; 72(5 Pt 1):615-20. PubMed ID: 10071548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Belgian multicenter clinical study of alfuzosin, a selective alpha 1-blocker, in the treatment of benign prostatic hyperplasia. The Alfuzosin Belgian Group.
    Schulman CC; De Sy W; Vandendris M; Tomas M; Santoni JP
    Acta Urol Belg; 1994 Dec; 62(4):15-21. PubMed ID: 7540794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Use of terazosin and alfuzosin in the treatment of benign prostatic hypertrophy (BPH): our experience].
    Larosa M; Ferretti S; Salsi P; Simonazzi M
    Acta Biomed Ateneo Parmense; 1994; 65(1-2):23-8. PubMed ID: 7528458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of short-term treatment with the alpha 1-blocker alfuzosin on urodynamic pressure/flow parameters in patients with benign prostatic hyperplasia.
    Martorana G; Giberti C; Di Silverio F; von Heland M; Rigatti P; Colombo R; Casadei G; Pacifico P
    Eur Urol; 1997; 32(1):47-53. PubMed ID: 9266231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urinary flow rates in patients with benign prostatic hypertrophy following treatment with alfuzosin. DUALF Group.
    Teillac P; Delauche-Cavallier MC; Attali P
    Br J Urol; 1992 Jul; 70(1):58-64. PubMed ID: 1379106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Worldwide experience with alfuzosin and tamsulosin.
    Michel MC; Flannery MT; Narayan P
    Urology; 2001 Oct; 58(4):508-16. PubMed ID: 11597528
    [No Abstract]   [Full Text] [Related]  

  • 19. [The treatment of patients with benign prostatic hyperplasia using the selective alpha-blocker alfuzosin].
    Mazo EB; Matushevskiĭ IA; Nikitin IuIu
    Ter Arkh; 1997; 69(10):79-82. PubMed ID: 9471799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical results with alpha-blockers in patients with symptomatic benign prostatic hyperplasia.
    Mensink HJ
    Prog Clin Biol Res; 1994; 386():285-9. PubMed ID: 7528396
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.